Balaxi Pharmaceuticals (NSE:BALAXI) 1-Year Sharpe Ratio: -0.56 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BALAXI Balaxi Pharmaceuticals Ltd NSE:BALAXI
63 GF Score
Price ₹22.40
GF Value ₹68.78
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Balaxi Pharmaceuticals 1-Year Sharpe Ratio?

Balaxi Pharmaceuticals NSE:BALAXI +0.45% 63 1-Year Sharpe Ratio is -0.56 as of Aug. 23, 2026. GuruFocus rates NSE:BALAXI with a GF Score™ of 63/100 and a GF Value™ of ₹68.78 (Possible Value Trap). The stock has 5 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-23), Balaxi Pharmaceuticals's 1-Year Sharpe Ratio is -0.56.

Balaxi Pharmaceuticals  (NSE:BALAXI) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Balaxi Pharmaceuticals 1-Year Sharpe Ratio Related Terms

NSE:BALAXI vs ZTS: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Balaxi Pharmaceuticals 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Balaxi Pharmaceuticals's 1-Year Sharpe Ratio falls into.


NSE:BALAXI
63GF Score
Balaxi Pharmaceuticals Ltd NSE:BALAXI
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Balaxi Pharmaceuticals 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.56 mean?
Balaxi Pharmaceuticals (NSE:BALAXI) has a 1-Year Sharpe Ratio of -0.56 as of Aug. 23, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Balaxi Pharmaceuticals and its competitors.
Is Balaxi Pharmaceuticals' 1-Year Sharpe Ratio too high?
Balaxi Pharmaceuticals' current 1-Year Sharpe Ratio is -0.56. Overall, Balaxi Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' 1-Year Sharpe Ratio compare to ZTS?
Balaxi Pharmaceuticals' 1-Year Sharpe Ratio of -0.56 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Balaxi Pharmaceuticals and its competitors. Balaxi Pharmaceuticals's current 1-Year Sharpe Ratio is -0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹68.78, compared to a current price of ₹22.40 — trading 67.4% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.56. Balaxi Pharmaceuticals' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current 1-Year Sharpe Ratio is -0.56 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?

Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued. The current stock price of ₹22.40 is trading 67.4% below its estimated GF Value™ of ₹68.78. GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.

Key valuation signals for NSE:BALAXI:

  • 1-Year Sharpe Ratio: -0.56
  • GF Value™: ₹68.78 vs. price of ₹22.40 (67.4% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Balaxi Pharmaceuticals Business Description

Address Phase-III, Road No: 81, Jubilee Hills, Plot No.409, H,No: 8-2-293, MAPS Towers, 3rd Floor, Hyderabad, TG, IND, 500 096
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
63GF Score

Get the complete analysis for NSE:BALAXI

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹22.40
Price
₹68.78
GF Value